QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems

Reuters

Jul 14

QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems

QuidelOrtho Corporation has announced a new partnership with BÜHLMANN Laboratories AG to introduce the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease $(IBD)$ and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23537) on July 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2551835041"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551835041\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551835041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-14 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551835041","market":"fut","top_or_hot":-1,"title":"QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QuidelOrtho Corporation has announced a new partnership with BÜHLMANN Laboratories AG to introduce the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a> and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23537) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-14 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        QuidelOrtho Corporation has announced a new partnership with BÜHLMANN Laboratories AG to introduce the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a> and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23537) on July 14, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL9JgPkr:1","article_id":"2551835041","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551835041","pubTimestamp":1752490831,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"QuidelOrtho Corporation has announced a new partnership with BHLMANN Laboratories AG to introduce the BHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease  and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","QDEL":"窥得儿医药","BK4082":"医疗保健设备"},"translate_title":"QuidelOrtho Corporation与BÜHLMANN Laboratories AG合作，在VITROS系统上推出创新的粪便生物标志物检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QDEL":0.9},"content_text":"QuidelOrtho Corporation Partners with BÜHLMANN Laboratories AG to Launch Innovative Fecal Biomarker Assays on VITROS Systems\n    \n\n        QuidelOrtho Corporation has announced a new partnership with BÜHLMANN Laboratories AG to introduce the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems. This collaboration aims to enhance gastrointestinal biomarker testing, specifically aiding in the diagnosis of inflammatory bowel disease $(IBD)$ and pancreatic insufficiency. The integration of these assays offers laboratories an efficient workflow, utilizing the CALEX Cap stool preparation device for optimized stool extraction. This partnership reflects a commitment to advancing diagnostics with non-invasive, patient-centric tools, ultimately improving patient care through fast and accurate test results.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quidelortho Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: LA23537) on July 14, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}